gastrointestinal tumours, colorectal 503PD A GENETIC RESPONSE PROFILE TO PREDICT EFFICACYOF ADJUVANT 5-FU IN COLON CANCER
نویسندگان
چکیده
I.K. Buhl1, S. Gerster2, M. Delorenzi3, T. Jensen4, P.B. Jensen4, N. Brunner1, A. Hansen4, S. Knudsen5 Department of Veterinary Disease Biology, Molecular Disease Biology, University of Copenhagen, Copenhagen, DENMARK Bioinformatics Core Facility, Swiss Institute Bioinformatics (SIB), Lausanne, SWITZERLAND Bioinformatics Core, Swiss Institute of Bioinformatics, Lausanne, SWITZERLAND Headquarters, Medical Prognosis Institute, Hoersholm, DENMARK US Office, Medical Prognosis Institute, Scottsdale, AZ, USA
منابع مشابه
Phase I trial of sulindac plus 5-fluorouracil and levamisole: potential adjuvant therapy for colon carcinoma.
Epidemiological studies indicate that nonsteroidal anti-inflammatory agents may reduce colorectal cancer incidence and mortality. Moreover, sulindac has been shown to attenuate the growth and progression of colonic neoplasms in an experimental model of colon carcinoma and in patients with familial adenomatous polyposis. To determine whether sulindac (300 mg/day) would increase toxicity associat...
متن کاملIs it Possible to Predict Benefit from 5FU Adjuvant Therapy in Stage III Colon Cancer Patients?
For more than three decades patients diagnosed with stage III sub-classify that stage with respect to the number of the involved colorectal cancers have undergone adjuvant chemotherapy based on fluoropyrimidines (5-FU) and more recently in combination with oxaliplatin (Dienstmann et al., 2015). Overall that treatment has reduced the risk of tumor recurrence and improved survival for patients wi...
متن کاملOral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial.
BACKGROUND Oral capecitabine achieves a superior response rate with an improved safety profile compared with bolus 5-fluorouracil-leucovorin (5-FU/LV) as first-line treatment for patients with metastatic colorectal cancer. We report here the results of a large phase III trial investigating adjuvant oral capecitabine compared with 5-FU/LV (Mayo Clinic regimen) in Dukes' C colon cancer. PATIENT...
متن کامل5-Fluorouracil Induce the Expression of TLR4 on HCT116 Colorectal Cancer Cell Line Expressing Different Variants of TLR4
Two common single nucleotide polymorphisms (SNPs) of the human TLR4 gene, namely Asp299Gly (D299G) and Thr399Ile (T399I), have been shown to impair the ability of certain individuals to respond properly to TLR4 ligands. 5-Fluorouracil (5-FU) is widely used for the treatment of patients with advanced colon cancers. The present study examined the impact of two common polymorphisms of the TLR4 gen...
متن کاملUse of capecitabine in management of early colon cancer
Capecitabine (Xeloda(®), Roche, Basel, Switzerland) is a pro-drug of 5-fluorouracil (5-FU), and it is converted to 5-FU in the cancer cell by enzymatic degradation. The role of capecitabine in colorectal cancer has evolved in the last 15 years. In early trials in the metastatic setting, capecitabine has shown superior response rates compared with those achieved with 5-FU (Mayo Clinic regimen) (...
متن کامل